Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting
December 05, 2019 08:15 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor...
Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results
November 07, 2019 16:01 ET
|
Zogenix, Inc.
Resubmitted NDA for FINTEPLA® for the treatment of Dravet syndromeEnrollment completed for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020Acquired Modis...
Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7
October 31, 2019 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome
October 25, 2019 09:00 ET
|
Zogenix, Inc.
Data have shown long-term, clinically meaningful convulsive seizure reduction (75.5%; p<0.001) in Dravet syndrome patients under 6 years old, as well as clinically meaningful and profound reduction...
Zogenix Completes Acquisition of Modis Therapeutics, Inc.
September 09, 2019 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully...
Zogenix Announces Acquisition of Modis Therapeutics, Inc.
August 26, 2019 07:00 ET
|
Zogenix, Inc.
Advances Zogenix’s strategy to provide transformative therapies to patients and families living with serious rare diseasesAdds MT1621, a proprietary, late-stage investigational medicine targeting...
Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome
July 08, 2019 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed...
Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
June 27, 2019 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that following receipt of final...
Zogenix Provides Corporate Update and Reports First Quarter 2019 Financial Results
May 08, 2019 16:01 ET
|
Zogenix, Inc.
Type A meeting with U.S. FDA expected by early June to discuss FINTEPLA® Dravet syndrome NDA expected by early JuneFINTEPLA Dravet syndrome MAA accepted for review by EMAExclusive distribution...
Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference
May 07, 2019 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D.,...